522 related articles for article (PubMed ID: 33566374)
1. Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.
Kokkinou M; Beishon LC; Smailagic N; Noel-Storr AH; Hyde C; Ukoumunne O; Worrall RE; Hayen A; Desai M; Ashok AH; Paul EJ; Georgopoulou A; Casoli T; Quinn TJ; Ritchie CW
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010945. PubMed ID: 33566374
[TBL] [Abstract][Full Text] [Related]
2. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
[TBL] [Abstract][Full Text] [Related]
3. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
[TBL] [Abstract][Full Text] [Related]
4. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.
McCleery J; Morgan S; Bradley KM; Noel-Storr AH; Ansorge O; Hyde C
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010633. PubMed ID: 25632881
[TBL] [Abstract][Full Text] [Related]
7. 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012883. PubMed ID: 29164600
[TBL] [Abstract][Full Text] [Related]
8. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
[TBL] [Abstract][Full Text] [Related]
9. Regional cerebral blood flow single photon emission computed tomography for detection of Frontotemporal dementia in people with suspected dementia.
Archer HA; Smailagic N; John C; Holmes RB; Takwoingi Y; Coulthard EJ; Cullum S
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD010896. PubMed ID: 26102272
[TBL] [Abstract][Full Text] [Related]
10. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Bonfill Cosp X; Flicker L
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012216. PubMed ID: 29164603
[TBL] [Abstract][Full Text] [Related]
11. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
13. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).
Arevalo-Rodriguez I; Smailagic N; Roqué I Figuls M; Ciapponi A; Sanchez-Perez E; Giannakou A; Pedraza OL; Bonfill Cosp X; Cullum S
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010783. PubMed ID: 25740785
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia.
Gloeckner SF; Meyne F; Wagner F; Heinemann U; Krasnianski A; Meissner B; Zerr I
J Alzheimers Dis; 2008 May; 14(1):17-25. PubMed ID: 18525124
[TBL] [Abstract][Full Text] [Related]
15. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
16. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
[TBL] [Abstract][Full Text] [Related]
17. Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI).
Arevalo-Rodriguez I; Smailagic N; Roqué-Figuls M; Ciapponi A; Sanchez-Perez E; Giannakou A; Pedraza OL; Bonfill Cosp X; Cullum S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD010783. PubMed ID: 34313331
[TBL] [Abstract][Full Text] [Related]
18. Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.
Chaudhry A; Houlden H; Rizig M
J Neurol Sci; 2020 Aug; 415():116886. PubMed ID: 32428759
[TBL] [Abstract][Full Text] [Related]
19. Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies.
Tang W; Huang Q; Wang Y; Wang ZY; Yao YY
J Neurol Sci; 2014 Oct; 345(1-2):26-36. PubMed ID: 25086857
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
Shea YF; Ha J; Chu LW
Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
